整合MBMA和QSP以确定重点共变量和预测复发性/阻断性多发性髓瘤治疗结果
Zeel Shah1, Clifton M Anderson2, Kevin D McCormick2
1Bristol Myers Squibb, Lawrenceville, New Jersey, USA.
CPT: pharmacometrics & systems pharmacology
|November 11, 2025
概括
基于模型的元分析 (MBMA) 和定量系统药理学 (QSP) 模型描述了复发性和耐火性多发性髓瘤 (RRMM) 疗法. 这种方法有助于对新型治疗方法的益处风险评估和决策.
科学领域:
- 在瘤学瘤学.
- 制药指标 (Pharmacometrics) 是一个指标.
- 生物统计学 生物统计学
背景情况:
- 复发性和耐火性多发性髓瘤 (RRMM) 提出了复杂的治疗挑战.
- 描述各种疗法的安全性和有效性概况对于优化患者护理至关重要.
- 现有的数据往往缺乏直接的比较证据,需要先进的分析方法.
研究的目的:
- 应用基于模型的元分析 (MBMA) 框架来评估RRMM疗法的安全性和有效性.
- 整合统计建模与机械模拟,使用定量系统药理学 (QSP) 进行综合评估.
- 在RRMM中支持基于模型的药物开发和临床决策.
主要方法:
- 利用已公布的MBMA临床试验数据,重点关注3级以上的中性质衰竭和整体反应率 (ORR).
- 开发并验证了统计模型,包括试验和治疗水平的共变量.
- 采用定量系统药理 (QSP) 建模来模拟患者对各种RRMM治疗的反应,包括新药.
主要成果:
- MBMA确定了基化剂增加的中性质减退风险和背景皮质类固醇或单次先前治疗更高的ORR.
- 根据MBMA的估计,它有助于在异质试验中进行系统的比较,并与标准进行基准测试.
- QSP模拟预测了不同治疗史的疗法特定ORR,包括虚拟患者和先前治疗分类器.
结论:
- 结合的MBMA和QSP方法为RRMM的利益风险评估提供了一个强大的框架.
- 这一综合战略通过将新疗法与不断变化的治疗环境进行比较,提高了临床决策.
- 该方法支持证据生成,特别是当对比试验不可用时.
更多相关视频
07:57Quantification of Protein Interaction Network Dynamics using Multiplexed Co-Immunoprecipitation
Published on: August 21, 2019
9.1K
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
30.4K
相关概念视频
01:24Kaplan-Meier Approach
547
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
547
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:21Cancer Survival Analysis
634
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
634